Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies

PHASE3CompletedINTERVENTIONAL
Enrollment

323

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Psoriasis
Interventions
DRUG

U0267 Foam

All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).

DRUG

Vehicle foam

All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).

Trial Locations (12)

14623

The Center for Dermatology at Lifetime Health, Rochester

27157

Wake Forest University Health Sciences, Winston-Salem

32175

Advanced Dermatology & Cosmetic Surgery, Ormond Beach

36608

Coastal Clinical Research, Inc., Mobile

37922

The Skin Wellness Center, PC, Knoxville

45219

University Dermatology Consultants, Inc., Cincinnati

66211

Adult & Pediatric Dermatology, Overland Park

78229

Dermatology Clinical Research Center of San Antonio, San Antonio

87106

Academic Dermatology Associates, Albuquerque

94538

Center for Dermatology Cosmetic and Laser Surgery, Fremont

97210

Oregon Dermatology and Research Center, Portland

02919

Clinical Partners, LLC, Johnston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Stiefel, a GSK Company

INDUSTRY